News & events

Strategy built around two complementary development axes: GMP Individualized Phage Therapies (IPT) and Phage Therapies Medicinal Products (PTMP)

On Individualized GMP Phages Therapies (IPT) Against Bacteria Responsible For ~ 70%(1) Of The Most Common Severe Resistant Infections

Promising clinical results observed in the first 88 patients evaluated so far

This non-comparative pilot study, including patients with Prosthetic Joint Infections (PJI), recruited 29 patients, 26 of whom were evaluable

Webinar being held today “Evolving strategic context for phages, Introducing new opportunities” to present PHAXIAM Therapeutics strategy

organized in collaboration with Phage Canada and bringing together international experts, highlighted the growing interest in phage therapy and the urgent need for a reference method for phagogram on an international scale

Cash and cash equivalents of €5.7 million as of September 30, 2024

PHAXIAM has received Investigational New Drug approval (IND) for its Phase II study, GLORIA, in Prosthetic Joint Infections (PJI) caused by Staphylococcus aureus (S. aureus). 

Sponsored by Assistance Publique – Hôpitaux de Paris (AP-HP) as part of the hospital-based clinical research program (PHRC)

Webinar (in French) today, September 25, 2024 at 6:00 pm CEST Click here to attend